Pasithea Therapeutics Corp Net Income
| KTTA Stock | USD 0.71 0.01 1.43% |
As of the 17th of February 2026, Pasithea Therapeutics holds the Semi Deviation of 7.86, risk adjusted performance of 0.058, and Coefficient Of Variation of 1666.4. Pasithea Therapeutics technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices.
Pasithea Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Pasithea Therapeutics' valuation are provided below:Gross Profit | Market Capitalization | Enterprise Value Revenue 277.4414 | Revenue | Earnings Share (4.43) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -2 M | -1.9 M | |
| Net Loss | -12.5 M | -13.1 M | |
| Net Loss | -12.5 M | -13.1 M | |
| Net Loss | (14.59) | (15.32) | |
| Net Income Per E B T | 1.18 | 1.22 |
Pasithea | Net Income | Build AI portfolio with Pasithea Stock |
Analyzing Pasithea Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Pasithea Therapeutics's current valuation and future prospects.
Latest Pasithea Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Pasithea Therapeutics Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Pasithea Therapeutics financial statement analysis. It represents the amount of money remaining after all of Pasithea Therapeutics Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Pasithea Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pasithea Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (13.9 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Pasithea Net Income Regression Statistics
| Arithmetic Mean | (4,253,318) | |
| Coefficient Of Variation | (152.01) | |
| Mean Deviation | 5,669,419 | |
| Median | (61,476) | |
| Standard Deviation | 6,465,383 | |
| Sample Variance | 41.8T | |
| Range | 15.9M | |
| R-Value | (0.80) | |
| Mean Square Error | 16.3T | |
| R-Squared | 0.63 | |
| Significance | 0.0001 | |
| Slope | (1,020,076) | |
| Total Sum of Squares | 668.8T |
Pasithea Net Income History
Other Fundumenentals of Pasithea Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Pasithea Therapeutics Net Income component correlations
Pasithea Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Pasithea Therapeutics is extremely important. It helps to project a fair market value of Pasithea Stock properly, considering its historical fundamentals such as Net Income. Since Pasithea Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pasithea Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pasithea Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. Expected growth trajectory for Pasithea significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pasithea Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.43) | Revenue Per Share | Quarterly Revenue Growth 14.981 | Return On Assets | Return On Equity |
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Pasithea Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Pasithea Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Pasithea Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Pasithea Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pasithea Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pasithea Therapeutics.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Pasithea Therapeutics on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Pasithea Therapeutics Corp or generate 0.0% return on investment in Pasithea Therapeutics over 90 days. Pasithea Therapeutics is related to or competes with Quoin Pharmaceuticals, Impact BioMedical, Kala Pharmaceuticals, AIM ImmunoTech, Alaunos Therapeutics, Vyne Therapeutics, and VivoSim Labs. Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric an... More
Pasithea Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pasithea Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pasithea Therapeutics Corp upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 9.5 | |||
| Information Ratio | 0.0561 | |||
| Maximum Drawdown | 137.41 | |||
| Value At Risk | (12.50) | |||
| Potential Upside | 13.95 |
Pasithea Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pasithea Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pasithea Therapeutics' standard deviation. In reality, there are many statistical measures that can use Pasithea Therapeutics historical prices to predict the future Pasithea Therapeutics' volatility.| Risk Adjusted Performance | 0.058 | |||
| Jensen Alpha | 0.8914 | |||
| Total Risk Alpha | (0.26) | |||
| Sortino Ratio | 0.1051 | |||
| Treynor Ratio | 0.379 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Pasithea Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Pasithea Therapeutics February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.058 | |||
| Market Risk Adjusted Performance | 0.389 | |||
| Mean Deviation | 7.37 | |||
| Semi Deviation | 7.86 | |||
| Downside Deviation | 9.5 | |||
| Coefficient Of Variation | 1666.4 | |||
| Standard Deviation | 17.81 | |||
| Variance | 317.28 | |||
| Information Ratio | 0.0561 | |||
| Jensen Alpha | 0.8914 | |||
| Total Risk Alpha | (0.26) | |||
| Sortino Ratio | 0.1051 | |||
| Treynor Ratio | 0.379 | |||
| Maximum Drawdown | 137.41 | |||
| Value At Risk | (12.50) | |||
| Potential Upside | 13.95 | |||
| Downside Variance | 90.28 | |||
| Semi Variance | 61.76 | |||
| Expected Short fall | (12.10) | |||
| Skewness | 4.54 | |||
| Kurtosis | 27.95 |
Pasithea Therapeutics Backtested Returns
Pasithea Therapeutics is out of control given 3 months investment horizon. Pasithea Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.098, which implies the firm had a 0.098 % return per unit of risk over the last 3 months. We were able to interpolate and analyze data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.79% are justified by taking the suggested risk. Use Pasithea Therapeutics Semi Deviation of 7.86, risk adjusted performance of 0.058, and Coefficient Of Variation of 1666.4 to evaluate company specific risk that cannot be diversified away. Pasithea Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The company holds a Beta of 2.79, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pasithea Therapeutics will likely underperform. Use Pasithea Therapeutics value at risk and the relationship between the expected short fall and market facilitation index , to analyze future returns on Pasithea Therapeutics.
Auto-correlation | -0.63 |
Very good reverse predictability
Pasithea Therapeutics Corp has very good reverse predictability. Overlapping area represents the amount of predictability between Pasithea Therapeutics time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pasithea Therapeutics price movement. The serial correlation of -0.63 indicates that roughly 63.0% of current Pasithea Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.63 | |
| Spearman Rank Test | -0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Pasithea Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Pasithea Therapeutics Corp reported net income of (13.9 Million). This is 104.07% lower than that of the Biotechnology sector and 119.85% lower than that of the Health Care industry. The net income for all United States stocks is 102.44% higher than that of the company.
Pasithea Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pasithea Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pasithea Therapeutics could also be used in its relative valuation, which is a method of valuing Pasithea Therapeutics by comparing valuation metrics of similar companies.Pasithea Therapeutics is currently under evaluation in net income category among its peers.
Pasithea Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Pasithea Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Pasithea Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pasithea Therapeutics' value.| Shares | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 0.0 | Armistice Capital, Llc | 2025-03-31 | 0.0 | Advisorshares Investments, Llc | 2025-06-30 | 193.5 K | Citadel Advisors Llc | 2025-06-30 | 46.9 K | Ubs Group Ag | 2025-06-30 | 42.1 K | Lpl Financial Corp | 2025-06-30 | 10 K | Hurley Capital, Llc | 2025-06-30 | 3.7 K | Tower Research Capital Llc | 2025-06-30 | 1.3 K | Sbi Securities Co Ltd | 2025-06-30 | 1.1 K | Royal Bank Of Canada | 2025-06-30 | 250 | Jpmorgan Chase & Co | 2025-06-30 | 150 |
Pasithea Fundamentals
| Return On Equity | -0.9 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 4.43 M | ||||
| Shares Outstanding | 22.4 M | ||||
| Shares Owned By Insiders | 1.52 % | ||||
| Shares Owned By Institutions | 22.90 % | ||||
| Number Of Shares Shorted | 264.67 K | ||||
| Price To Book | 1.34 X | ||||
| Price To Sales | 42.15 X | ||||
| Gross Profit | (2.21 K) | ||||
| EBITDA | (13.6 M) | ||||
| Net Income | (13.9 M) | ||||
| Cash And Equivalents | 47.94 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 1.28 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 51.17 X | ||||
| Book Value Per Share | 1.64 X | ||||
| Cash Flow From Operations | (13.92 M) | ||||
| Short Ratio | 0.21 X | ||||
| Earnings Per Share | (4.43) X | ||||
| Target Price | 3.0 | ||||
| Beta | 0.21 | ||||
| Market Capitalization | 25.09 M | ||||
| Total Asset | 16.06 M | ||||
| Retained Earnings | (49.58 M) | ||||
| Working Capital | 6.25 M | ||||
| Net Asset | 16.06 M |
About Pasithea Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pasithea Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pasithea Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pasithea Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:Check out You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. Expected growth trajectory for Pasithea significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pasithea Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.43) | Revenue Per Share | Quarterly Revenue Growth 14.981 | Return On Assets | Return On Equity |
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Pasithea Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Pasithea Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Pasithea Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.